Nutritional Psychiatry
September 1, 2026
Agnieszka Mechlińska, Aleksander Kwaśny, Michał Pastuszak et al.
ABSTRACT Psychedelic compounds exhibit diverse pharmacological and clinical effects, underscoring the need for further research and the development of clear guidelines to support their safe and effective clinical use. Growing interest in psychedelics has also increased attention toward the relationship between nutrition, dietary habits, and psychiatric disorders. This narrative review presents...
Journal of Affective Disorders
August 15, 2026
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
Anhedonia, a core symptom of major depressive disorder (MDD), is associated with illness severity, suicide risk, poor functioning, and predicts poor response to antidepressants. While no treatments are approved, ketamine and esketamine show promise in reducing anhedonia. This study examines clinical and sociodemographic features linked to anhedonia treatment response in treatment-resistant...
European Psychiatry
June 1, 2026
Michał Pastuszak, Katarzyna Jakuszkowiak‐wojten, Maria Gałuszko‐węgielnik et al.
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
European Psychiatry
June 1, 2026
Agnieszka Mechlińska, Damian Swieczkowski, Aleksander Kwaśny et al.
Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...
Pharmacol Rep
May 20, 2026
Aleksander Kwaśny, Alina Wilkowska, Michał Pastuszak et al.
Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.
Therapeutic Advances in Psychopharmacology
2026
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al.
Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-resistant bipolar depression (TRBD) do not respond. This study aimed to identify clinical and sociodemographic characteristics that are associated with nonresponse of anhedonia following short-term ketamine treatment in TRBD. A retrospective analysis...
Neuropsychopharmacology Reports
July 20, 2025
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al.
3 citations
OBJECTIVES: Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response. This study explored features of ketamine nonresponse in TRBD. METHODS: In a post hoc analysis of a naturalistic study, 35 TRBD patients received a four-week ketamine regimen (intravenous 0.5 mg/kg or oral 2.0/2.5 mg/kg)....
Pharmacological reports : PR
April 30, 2025
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
3 citations
Ketamine is currently gaining attention as a rapid-acting antidepressant for treatment-resistant depression (TRD). However, many patients fail to respond, and limited data exist on predictors of non-response. This study aims to characterize the sociodemographic and clinical features associated with non-response to ketamine among TRD patients. This is a post-hoc analysis of a naturalistic...
Drugs - real world outcomes
December 1, 2024
Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny
3 citations
Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management strategies to achieve functional recovery. This observational study aimed to evaluate the impact of ketamine infusions on depressive symptoms in patients with bipolar disorder who continued their baseline psychotropic and chronic somatic treatments....
Asian Journal of Psychiatry
September 1, 2024
Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny
8 citations
Symptoms that emerge during pharmacological treatment of bipolar depression are frequently observed, underscoring the necessity for comprehensive treatment monitoring. This observational study sought to observe the correlation of eight intravenous ketamine infusions with treatment-emergent depressive symptoms in treatment-resistant bipolar depression patients who maintained their baseline...
Frontiers in Neuroscience
July 11, 2023
Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Mariusz S. Wiglusz et al.
8 citations
Background: Psychotic treatment-resistant depression represents a complex and challenging form of mood disorder in clinical practice. Despite its severity, psychotic depression is frequently underdiagnosed and inadequately treated. Ketamine has demonstrated rapid and potent antidepressant effects in clinical studies, while exhibiting a favorable safety and tolerability profile. Although there...